BMS-823778 (2), a 1,2,4-triazolopyridinyl-methanol derived analog, was identified as a potent and selective inhibitor of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) enzyme (IC50 = 2.3 nM) with >10,000-fold selectivity over 11β-HSD-2. Compound 2 exhibits robust acute pharmacodynamic effects in cynomolgus monkeys (ED50 = 0.6 mg/kg) and in diet-induced obese (DIO) mice (ED50 = 34 mg/kg). Compound 2 also showed excellent inhibition in an ex vivo adipose DIO mouse model (ED50 = 5.2 mg/kg). Oral bioavailability ranges from 44% to 100% in preclinical species. Its favorable development properties, pharmacokinetics, high adipose-to-plasma concentration ratio, and preclinical pharmacology profile have prompted the evaluation of 2 for the treatment of type 2 diabetes and metabolic syndrome in phase 2 clinical trials.

中文翻译：

---

发现作为人11β-羟基类固醇脱氢酶1（11β-HSD-1）抑制剂的临床候选药物BMS-823778。

BMS-823778（2）是一种1,2,4-三唑并吡啶基-甲醇衍生的类似物，被确定为1β型11β-羟类固醇脱氢酶（11β-HSD-1）酶的强效和选择性抑制剂（IC50 = 2.3 nM）相对于11β-HSD-2具有> 10,000倍的选择性。化合物2在食蟹猴（ED50 = 0.6 mg / kg）和饮食诱发的肥胖（DIO）小鼠（ED50 = 34 mg / kg）中表现出强大的急性药效作用。化合物2在离体脂肪DIO小鼠模型中也显示出优异的抑制作用（ED50 = 5.2 mg / kg）。临床前物种的口服生物利用度范围为44％至100％。它具有良好的开发性能，药代动力学，高的脂肪对血浆浓度比以及临床前药理学特性，促使2期临床试验对2型糖尿病和代谢综合征的治疗进行了评估。